发布求助
文献互助 智能选刊 最新文献

Gastroenterology and Hepatology最新文献

筛选
英文 中文
Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients With Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial. VK2809在活检证实的非酒精性脂肪性肝炎和纤维化患者中的52周2b期VOYAGE试验结果：一项随机、安慰剂对照试验
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Results From the 52-Week Phase 2b VOYAGE Trial of VK2809 in Patients With Biopsy-Confirmed Non-Alcoholic Steatohepatitis and Fibrosis: A Randomized, Placebo-Controlled Trial.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"13-14"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints. Plecanatide对肠易激综合征伴便秘和腹胀患者有效：使用三症状复合终点进行评估。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Plecanatide Is Efficacious in Patients With Irritable Bowel Syndrome With Constipation and Bloating: Evaluation Using Trisymptom Composite Endpoints.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study. 中至重度活动性溃疡性结肠炎患者临床缓解和内镜改善状态的利桑单抗维持治疗的疗效：COMMAND 3期研究的事后分析
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 10","pages":"8-9"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessment of Resmetirom Efficacy (80 mg vs. 100 mg) Stratified by Baseline Body Mass Index and Weight in Patients From the MAESTRO-NASH Trial. 根据MAESTRO-NASH试验患者的基线体重指数和体重分层评估瑞司替龙的疗效（80 mg vs 100 mg）。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Assessment of Resmetirom Efficacy (80 mg vs. 100 mg) Stratified by Baseline Body Mass Index and Weight in Patients From the MAESTRO-NASH Trial.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"12-13"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-Year Treatment With Elafibranor in the Phase 3 ELATIVE Trial Improves GLOBE and UK-PBC Prognostic Scores. 在3期相对试验中，一年的elafbranor治疗可改善GLOBE和UK-PBC预后评分。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"One-Year Treatment With Elafibranor in the Phase 3 ELATIVE Trial Improves GLOBE and UK-PBC Prognostic Scores.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 12","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784548/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Liver Enzymes Reductions From Baseline Over Time in Resmetirom-Treated Patients in a Phase 3 Study, MAESTRO-NASH. 在一项3期研究中，雷司替龙治疗的患者肝酶随时间从基线降低，MAESTRO-NASH。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Liver Enzymes Reductions From Baseline Over Time in Resmetirom-Treated Patients in a Phase 3 Study, MAESTRO-NASH.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"14-15"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resmetirom Effects on NASH With Liver Fibrosis in Patients With NASH Genetic Risk Alleles. 瑞司替康对NASH合并肝纤维化患者遗传风险等位基因的影响
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Resmetirom Effects on NASH With Liver Fibrosis in Patients With NASH Genetic Risk Alleles.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 11","pages":"16-17"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Weight on the Efficacy, Time to Response, and Safety of Linaclotide in Adults With Chronic Idiopathic Constipation or Irritable Bowel Syndrome With Constipation: Post Hoc Descriptive Analysis by Body Mass Index. 体重对利那洛肽对成人慢性特发性便秘或肠易激综合征伴便秘的疗效、反应时间和安全性的影响：体重指数的事后描述性分析
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Impact of Weight on the Efficacy, Time to Response, and Safety of Linaclotide in Adults With Chronic Idiopathic Constipation or Irritable Bowel Syndrome With Constipation: Post Hoc Descriptive Analysis by Body Mass Index.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"9-10"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS in America 2024 Real-World Survey. 肠易激综合征伴便秘对患者整体健康状况和生活质量构成重大负担：来自美国IBS 2024年真实世界调查的结果
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Irritable Bowel Syndrome With Constipation Poses a Substantial Burden to Patient Overall Health Status and Quality of Life: Results From the IBS in America 2024 Real-World Survey.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"2-3"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation. 肠易激综合征合并便秘或慢性特发性便秘患者停药的原因。
Gastroenterology and Hepatology Pub Date : 2024-12-01
{"title":"Reasons for Treatment Discontinuation in Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":52498,"journal":{"name":"Gastroenterology and Hepatology","volume":"20 12 Suppl 9","pages":"3-5"},"PeriodicalIF":0.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11784540/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143082033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信